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DCAF1 controls T-cell function via p53-dependent
and -independent mechanisms
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Yue Xiong1,3, Xian Chen1,3 & Yisong Y. Wan1,2,5
On activation, naive Tcells grow in size and enter cell cycle to mount immune response. How
the fundamental processes of T-cell growth and cell cycle entry are regulated is poorly
understood. Here we report that DCAF1 (Ddb1–cullin4-associated-factor 1) is essential for
these processes. The deletion of DCAF1 in T cells impairs their peripheral homeostasis.
DCAF1 is upregulated on T-cell receptor activation and critical for activation-induced T-cell
growth, cell cycle entry and proliferation. In addition, DCAF1 is required for T-cell expansion
and function during anti-viral and autoimmune responses in vivo. DCAF1 deletion leads to a
drastic stabilization of p53 protein, which can be attributed to a requirement of DCAF1 for
MDM2-mediated p53 poly-ubiquitination. Importantly, p53 deletion rescues the cell cycle
entry defect but not the growth defect of DCAF1-deficient cells. Therefore, DCAF1 is vital for
T-cell function through p53-dependent and -independent mechanisms.
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M
ature naive T cells in the periphery remain quiescent
with virtually undetectable cell growth (biomass
increase due to elevated metabolism and biosynthesis)
or proliferation under steady state. On antigenic stimulation,
naive T cells grow in size followed by cell cycle entry and rapid
proliferation to become effector T cells1,2. When the antigenic
stimuli diminish, most of the effector T cells die and the others
return to quiescence. The quiescent effector/memory T cells
readily enter cell cycle and to proliferate when they are
re-stimulated with antigen and mitogen. Activation-induced
cell cycle entry and proliferation of T cells are central for
T-cell-mediated immune response. Deregulated T-cell
proliferation often leads to debilitating and fatal diseases
including immune deficiency, chronic inflammation,
autoimmunity and leukaemia3,4. Nonetheless, how T-cell
receptor (TCR) signalling and cell cycle regulation are
coordinated remains largely unaddressed. Specifically, how the
fundamental processes of activation induced T-cell growth and
cell cycle entry are regulated is poorly understood. We therefore
investigated factors upregulated by TCR activation in T cells and
found DCAF1 expression to be highly induced.
DCAF1, also known as VprBP (HIV-1 viral protein r-binding
protein), is an evolutionary conserved substrate-binding subunit of
CRL4 (Cul4a–Ddb1–Roc1) ubiquitin ligase complex5–8. It is a
cellular protein targeted by HIV-1 viral protein R (Vpr)9. The
function of DCAF1 in mammalian cells attracted much attention
recently. DCAF1 modulates cellular response against HIV in
macrophages10,11, controls the survival and reprogramming of
oocyte12,13, and regulates G2/M transition14–22. DCAF1 functions
through diverse mechanisms including regulating protein poly-
ubiquitination, mono-ubiquitination and phosphorylation13,23–25.
Nonetheless, whether and how DCAF1 controls the function of
primary T cell, a major cell type infected by HIV26, remains
unknown.
We studied the role for DCAF1 in T cells by deleting DCAF1
specifically in these cells. The disruption of DCAF1 impairs the
peripheral maintenance of T cells. DCAF1 is required for the cell
growth and cell cycle entry of activated T cells. DCAF1 deletion
abrogates T-cell expansion during anti-viral and autoimmune
responses in vivo. DCAF1-deficient cells drastically stabilize p53
protein with elevated expression of p53 target genes, which is
attributed to a requirement of DCAF1 for MDM2-promoted
p53 poly-ubiquitination. Intriguingly, we found that although p53
deletion failed to correct the T-cell growth defect due to DCAF1
deletion, it restored the cell cycle entry of DCAF1-deficient
T cells. These findings demonstrate an essential role for DCAF1
in T-cell homeostasis and the growth and cell cycle entry of
activated T cells. In addition, this study identifies p53 a critical
downstream factor of DCAF1 in controlling cell cycle entry.
Results
DCAF1 expression in naive and activated T cells. To identify
factors upregulated during T-cell activation, we purified naive
CD4 T cells from wild-type mice and stimulated them with anti-
CD3 and anti-CD28. We found that, on TCR ligation, T-cell size
grew gradually to reach a twofold increase in diameter by 24 h
(Fig. 1a), associating with elevated protein contents (Fig. 1b). The
cell growth could be readily detected by flow-cytometry (Fig. 1c).
The hallmark for cell cycle entry is the DNA synthesis and sub-
sequent cell division. Using BrdU incorporation assay, we found
that while the DNA synthesis of non-activated naive T cells was
virtually undetectable that of TCR-activated T cells started at
12 h, became evident at 18 h and reached a high level at 24 h post
activation (Fig. 1d), followed by rapid cell division (Fig. 1e). Using
this experimental system, we identified factors upregulated by
TCR stimulation and found that the protein expression of
DCAF1 was low in naive T cells and drastically upregulated
during activation-induced T-cell growth and cell cycle entry
(Fig. 1f), although the mRNA expression appeared largely
unchanged (Fig. 1g). We therefore hypothesized that DCAF1 was
involved in activated T-cell function.
The development and homeostasis of Cd4Cre;Dcaf1fl/fl T cells.
To study the function of DCAF1 in T cells, we deleted DCAF1
specifically in mature T cells by crossing Cd4Cre mice27 with
Dcaf1fl/fl mice15. Cd4Cre;Dcaf1fl/fl mice were born at the
Mendelian ratio and phenotypically grossly normal. T-cell
development was largely normal in Cd4Cre;Dcaf1fl/fl mice.
Compared with Cd4Cre;Dcaf1fl/þ littermates, Cd4Cre;Dcaf1fl/fl
mice had similar percentages of double negative (DN) and double
positive, but slightly less CD4SP (single positive) and CD8SP
thymocytes (Fig. 2a) that express similar amounts of maturation
markers (Supplementary Fig. 1a–c). The percentages and
numbers of mature CD4þ and CD8þ T cells in the peripheral
lymphoid organs were lower in Cd4Cre;Dcaf1fl/fl than in
Cd4Cre;Dcaf1fl/þ mice (Fig. 2a and Supplementary Fig. 1d).
Nonetheless, abundant numbers of naive (CD62LhighCD44low)
mature T cells could be recovered from Cd4Cre;Dcaf1fl/fl mice
(Fig. 2b, Supplementary Fig. 1d,e) with efficient deletion of
DCAF1 protein (Fig. 2c). These findings suggest DCAF1 deletion
affects the homeostasis of mature T cells.
To further investigate whether DCAF1 is required for T-cell
peripheral maintenance via a cell-intrinsic mechanism, we
generated mixed-bone-marrow chimeric mice where wild-type
(CD45.1þCD45.2þ ) and Cd4Cre;Dcaf1fl/fl (CD45.2þ ) T cells
were generated and maintained in the same host (CD45.1þ ).
We found that Cd4Cre;Dcaf1fl/fl thymocyte development was
moderately defective in the chimera mice (Fig. 2d) and that
DCAF1-deficient mature T cells were poorly maintained in the
periphery when compared with wild-type cells (Fig. 2e). We
also noticed that, compared with co-existing wild-type T cells,
DCAF1-deficient mature T cells in the chimeras were composed
of predominantly naive (CD62highCD44low) and much fewer
effector/memory (CD62LlowCD44high) T cells (Fig. 2f and
Supplementary Fig. 1f), suggesting that DCAF1 deletion was
more detrimental to the maintenance of effector/memory T cells
than that of naive T cells. The relatively normal distribution
of effector/memory T-cell population in Cd4Cre;Dcaf1fl/fl mice
(Fig. 2b) was therefore likely due to the lymphopenia-drive
aberrant T-cell activation28. These findings thus demonstrate that
DCAF1 is required for T-cell homeostasis in a cell-intrinsic
manner.
DCAF1 is vital for activated T cell growth and cell cycle entry.
The upregulation of DCAF1 on TCR stimulation (Fig. 1f) indicated
its potential importance for activation-induced T-cell growth and
cell cycle entry. To test this, we purified naive CD4 T cells from
wild-type and Cd4Cre;Dcaf1fl/fl mice and activated them with anti-
CD3 and anti-CD28. We found that DCAF1-deficient naive T cells
failed to enlarge in size (Fig. 3a, Supplementary Fig. 2a) or to
increase cellular protein amounts after TCR activation (Supple-
mentary Fig. 2b), although the upregulation of T-cell activation
markers, including CD69, CD25 and CD44, was comparable
between wild-type and DCAF1-deficient T cells (Supplementary
Fig. 2c). In addition, the proliferation of DCAF1-deficient T cells
was completely abolished (Fig. 3b). While DCAF1 has been shown
to be involved in G2/M transition during cell cycle14–22, the
proliferation defect observed in DCAF1-deficient T cells appeared
primarily due to defective cell cycle entry. In the absence of
DCAF1, the S-phase entry did not occur in activated naive T cells
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(Fig. 3c), associating with reduced cyclin expression (Supple-
mentary Fig. 2d) and Rb hyper-phosphorylation (Fig. 3d), a critical
step required for cell cycle entry29,30. Besides abolished T-cell
growth and cell cycle entry, activated DCAF1-deficient T cells were
more prone to apoptosis than wild-type cells (Supplementary
Fig. 2e).
The decreased T-cell number in Cd4Cre;Dcaf1fl/fl mice (Fig. 2a)
may lead to a partial lymphopenic environment that could
adversely affect T-cell function28. To study the cell-intrinsic
defect of DCAF1-deficient T cells, we compared the functions of
wild-type and DCAF1-deficient T cells developed together in the
mixed-bone-marrow chimera (described in Fig. 2d–f). Compared
with co-existing wild-type T cells, DCAF1-deficient T cells failed
to grow in size after TCR activation (Fig. 3e), although they
upregulated T-cell activation markers normally (data not shown).
In addition, the proliferation and the cell cycle entry of
DCAF1-deficient T cells were abolished (Fig. 3f,g). These
findings demonstrated that DCAF1 is intrinsically required for
T-cell growth and cell cycle entry in response to TCR activation.
Cytokine-stimulated cell cycle entry requires DCAF1. Cell
growth occurs slightly earlier than cell cycle entry in naive T cells
after TCR activation (Fig. 1a–d). Thus, the defect of cell cycle
entry observed in DCAF1-deficient naive T cells (Fig. 3c,f) could
be a consequence of failed T-cell growth (Fig. 3a,e). To address
whether DCAF1 is specifically required for cell cycle entry of
activated T cells, we used effector T-cell re-stimulation model.
In this model, naive T cells were activated by anti-CD3 and
anti-CD28 under culturing conditions. Five days later, most of
the activated T cells ceased cell cycle and returned to quiescent
state with minimal DNA synthesis when no further stimulation
was provided (Supplementary Fig. 3a). On cytokine IL-2
re-stimulation, the quiescent effector T cells re-entered cell cycle
with a high rate of DNA synthesis (Supplementary Fig. 3a) but
without obvious cell growth (Supplementary Fig. 3b,c). Therefore,
re-stimulation of quiescent effector T cells can be used as a model
to specifically study the cell cycle entry independent of cell
growth.
To investigate if DCAF1 is required for cell cycle entry of
effector T cells, we crossed Dcaf1fl/fl mice15 with tamoxifen-
inducible-Cre (ERCre) mice31 to delete DCAF1 at the time of our
choice. On 4-hydroxy-tamoxifen treatment in vitro, the protein
expression of DCAF1 in ERCre;Dcaf1fl/fl T cells was greatly
reduced by 24 h and abolished by 48 h after TCR activation
(Fig. 4a). We then compared cell growth and proliferation of
mixed wild-type (CD45.1þ ) and ERCre;Dcaf1fl/fl (CD45.2þ )
T cells following TCR activation under the same culturing
conditions. Because cell growth occurred before DCAF1 was fully
deleted, the sizes of wild-type and ERCre;Dcaf1fl/fl T cells were
comparable (Fig. 4b). In addition, the rates of cell division
(Fig. 4c) and DNA synthesis (Fig. 4d) were slightly lower in
ERCre;Dcaf1fl/fl than in wild-type T cells. Therefore, this
experimental system allows us to generate DCAF1-deficient
effector T cells to study whether DCAF1 is required for
IL-2-stimulated cell cycle entry in effector T cells as described
in Supplementary Fig. 3. We found that while wild-type
(CD45.1þ ) effector T cells readily entered cell cycle on IL-2
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Figure 1 | Activation-induced cell growth and cell cycle entry of T cells. (a–c) Naive CD4þ T cells were activated by anti-CD3 and anti-CD28. At
indicated time points after activation, cell growth was analysed by microscopy for morphology (a), by bicinchoninic acid assay (BCA) assay for protein
amount (b), and by flow-cytometry for cell size (c). Means±s.d. of three experiments are shown (*Po0.05 by Student’s t-test; NS, not significant, P40.05
by Student’s t-test). Representative results of at least three independent experiments are shown. (d,e) The amount of DNA synthesis was determined by
BrdU incorporation (d), and the proliferation was assessed by CFSE dilution (e) of CD4þ naive T cells activated by anti-CD3 and anti-CD28 at indicated
time points. Results are representative of three experiments. (f,g) The expression of DCAF1 was monitored by immunoblotting (f) and quantitative reverse
transcription–PCR (g) assays at indicated time points after CD4þ naive T cells were activated by anti-CD3 and anti-CD28. Results are representative of
three experiments.
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Figure 2 | DCAF1 regulates T-cell development and homeostasis. (a) The distribution of various T-cell populations in the thymus, spleen and periphery lymph
nodes (PLN) of mice with different genotypes, assessed by flow-cytometry. The bar graphs show the means±s.d. of four sets of mice (*Po0.05 by Student’s
t-test). (b) The distribution of naive (CD62LhighCD44low) and effector/memory (CD62LlowCD44high) CD4þ Tcells in the spleen and periphery lymph node (PLN)
of mice with different genotypes, assessed by flow-cytometry. The bar graphs show the means±s.d. of four sets of mice (NS, not significant, P40.05 by Student’s
t-test). (c) DCAF1 protein expression in CD4þ and CD8þ Tcells sorted from mice of different genotypes, analysed by immunoblotting. The immunoblotting is
representative of at least three experiments. (d) The comparison of the thymocyte populations in the irradiated recipient chimeric mice (CD45.1þ ) reconstituted
with equal numbers of bone marrow cells from wild-type mice (CD45.1þCD45.2þ ) and Cd4Cre;Dcaf1fl/fl mice (CD45.2þ ). The bar graphs show the means±s.d.
of data from five recipient mice (*Po0.05 by Student’s t-test). (e) The comparison of CD4þ and CD8þ Tpopulations in the spleens and periphery lymph nodes
(PLN) of the recipient chimeric mice. The bar graphs show the means±s.d. of data from five recipient mice (*Po0.05 by Student’s t-test). (f) The comparison of
naive (CD62LhighCD44low) and effector/memory (CD62LlowCD44high) CD4þ Tcells in the spleens and periphery lymph nodes (PLN) of the recipient chimeric
mice. The bar graphs show the means±s.d. of data from five recipient mice (*Po0.05 by Student’s t-test). See also Supplementary Fig. 1.
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re-stimulation, DCAF1-deficient T cells (CD45.2þ ) failed to
synthesize DNA under the same conditions (Fig. 4e). Such a
requirement of DCAF1 for cell cycle entry of T cells appeared to
be independent of cell growth because the sizes of wild-type and
DCAF1-deficient T cells were virtually identical during
quiescence and after IL-2 re-stimulation (Fig. 4f). These results
suggest that DCAF1 controls cell cycle entry.
DCAF1 controls T cell responses in vivo. Antigen-induced
clonal expansion is critical for T-cell immunity. Aforementioned
findings in cell culture condition encouraged us to investigate
whether DCAF1 was required for T-cell clonal expansion and
function in vivo during infection and autoimmunity. We first
addressed if DCAF1 deletion affected T-cell clonal expansion in
response to lymphocytic choriomeningitis virus (LCMV) infec-
tion. We crossed Cd4Cre;Dcaf1fl/fl mice with SMARTA TCR
transgenic mice, whose CD4þ T cells can be specifically activated
by LCMV peptide GP61–80 (ref. 32). CD4þ T cells from
Cd4Cre;Dcaf1fl/þ ;SMARTA mice (CD45.2þ ) and Cd4Cre;
Dcaf1fl/fl;SMARTA mice (CD45.1þCD45.2þ ) were purified,
mixed at the ratio of 1:1, and then transferred into syngeneic
wild-type recipient mice (CD45.1þ ). Recipient mice were then
infected with LCMV (Amstrong strain) to activate transferred
T cells. While DCAF1-sufficient SMARTA T cells expanded
dramatically in response to LCMV infection; DCAF1-deficient
SMARTA T cells failed to expand in the same hosts (Fig. 5a,b).
We next examined whether DCAF1 controls T-cell function in
an autoimmune disease model, experimental autoimmune
encephalomyelitis (EAE), by immunizing mice with myelin
oligodendrocyte (MOG) peptide emulsified in complete Freund’s
adjuvant (CFA). While wild-type mice developed EAE,
Cd4Cre;Dcaf1fl/fl mice were refractory to MOG/CFA-induced
EAE (Fig. 5c). Further analysis showed that much less T cells were
recovered from the spinal cords of Cd4Cre;Dcaf1fl/fl mice when
compared with wild-type mice (Fig. 5d). These results indicate
that DCAF1 is essential for T-cell clonal expansion in vivo and for
T-cell-mediated anti-viral and autoimmune response.
DCAF1 interacts with COP9 signalosome. The findings that
DCAF1 is required for cell size growth and cell cycle entry from
quiescence promoted us to investigate the underlying molecular
mechanisms. To identify the cellular factors that associate with
DCAF1 in T cells, we analysed DCAF1-interacting proteins
using mass spectrometry (MS). DCAF1 co-immunoprecipitated
products from CD4þ T cells were subjected to MS analysis as
described previously33,34. In agreement with previous finding, we
found that DCAF1 interacted with the components of
CRL4 complex including DDB1 and CUL4 in T cells (Fig. 6a
and Supplementary Table 1). Of interest, the prominent
DCAF1-interacting proteins in T cells belong to COP9
signalosome. The interaction of DCAF1 with CSN1 and CSN2
(two important components of COP9 signalosome) was verified
by co-immunoprecipitation (co-IP) assay (Fig. 6b). Further
analysis of protein–protein interaction network based on
STRING database showed that COP9 signalosome subunits and
CRL4 components interacted with each other (Fig. 6c). Therefore
DCAF1 belongs to a mega-complex-containing multiple subunits
of CRL4 complex and COP9 signalosome in T cells. COP9
signalosome is critical for T-cell function. Deletion of CSN8
(a subunit of COP9 signalosome) destabilizes the components of
COP9 signalosome and leads to defective cell cycle entry in
T cells35. It is therefore possible that DCAF1 deletion destabilized
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Figure 3 | DCAF1 is required for cell growth and cell cycle entry. (a–d) The comparison of the sizes (a), the proliferation (b), the DNA synthesis (c) and
the amount of Rb protein (pRb) and its phosphorylation (p-pRb) (d) of CD4þ naive T cells with different genotypes at indicated time points after
being activated with anti-CD3 and anti-CD28. The bar graphs show the means±s.d. of data from five experiments (*Po0.05 by Student’s t-test).
(e–g) The comparison of the cell sizes (e), the DNA synthesis (f) and the proliferation (g) of CD4þ T cells of different genotypes co-existing in the
mixed-bone-marrow chimeric mice described in Fig. 2d–f at indicated time points after TCR activation. The bar graphs show the means±s.d. of data from
four experiments (*Po0.05 by Student’s t-test). See also Supplementary Fig. 2.
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the components of COP9 signalosome. The stability of the
components of COP9 signalosome, however, appeared normal
in the absence of DCAF1. The protein levels of CSN1 and
CSN2 were comparable between DCAF1-sufficient and DCAF1-
deficient T cells (Fig. 6d). Notably, the expression of CUL4A and
DDB1 and the neddylation of CUL4A35 appeared normal in the
absence of DCAF1 (Fig. 6e). These findings therefore suggest that
DCAF1 is a critical component of CRL4–COP9 mega-complex in
controlling cell growth and cell cycle entry.
DCAF1 deficiency leads to p53 protein stabilization. We
further investigated whether DCAF1 deletion affected the
expression of critical regulators for cell growth and cell cycle
entry. Because c-Myc and p53 have been shown to be critical for
the cell growth and cell cycle entry2,36–38, we investigated if
DCAF1 deletion affected the expression of c-Myc and p53 and
found that the p53 and its target p21 cell cycle inhibitor were
more abundantly expressed in DCAF1-deficient than in wild-type
T cells after TCR activation. In addition, TCR-activated c-Myc
upregulation was reduced in DCAF1-deficient T cells (Fig. 7a
and Supplementary Fig. 4a). The expression and downregulation
of p27 cell cycle inhibitor was, however, unperturbed in
DCAF1-deficient T cells (Supplementary Fig. 4b). In agreement
with the increased p53 expression, the mRNA levels of p53
target genes including p21 and Bax39–41 were elevated in
DCAF1-deficient T cells (Fig. 7b), contributing to impaired cell
cycle entry and increased apoptosis (Fig. 3 and Supplementary
Fig. 2e). Because DCAF1 was deleted in CD4Cre;Dcaf1fl/fl T cells
long before the TCR activation, some of the DCAF1-dependent
changes (Fig. 7a,b) may not be a primary effect of DCAF1
deletion. We therefore further studied how the p53 and c-Myc
expression was affected when DCAF1 was acutely deleted. Using
ERCre;Dcaf1fl/fl T cells, we deleted DCAF1 acutely in vitro as
described in Fig. 4a. We found that p53 protein level greatly
elevated at the time of DCAF1 deletion (Fig. 7c) with increased
mRNA expression of p53 target genes p21 and Bax (Fig. 7d),
whereas c-Myc expression did not obviously change (Fig. 7c).
Therefore, increased expression of p53 was one of the primary
effects of DCAF1 deletion. Using ERCre;Dcaf1fl/fl T cells, we also
assessed how DCAF1 deletion affected p53 expression in
quiescent effector T cells and IL-2-stimulated effector T cells.
p53 and its target genes including p21 and Bax were expressed at
higher levels in DCAF1-deficient than in DCAF1-sufficient
effector T cells during quiescence and IL-2 stimulated cell cycle
entry (Fig. 7e,f). Proteasome-mediated protein degradation is a
primary means to control p53 expression in non-lymphoid
cells42. We found a drastic stabilization of p53 in activated
wild-type T cells treated with proteasome inhibitor MG132,
although MG132 treatment did not further increase p53 amount
in DCAF1-deficient cells (Fig. 7g), suggesting that DCAF1
deletion led to p53 protein stabilization. Indeed, the half-life of
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p53 was much longer in DCAF1-deficient than in
DCAF1-sufficient T cells (Fig. 7h). Thus DCAF1 deletion leads
to p53 protein stabilization.
To understand how DCAF1 regulates p53 stabilization, we
analysed the DCAF1-interacting protein profile in T cells by
co-IP MS analysis. DCAF1 interacted with CRL4 components
and COP9 signalosome subunits in a mega-complex in CD4 T
cells (Fig. 6c). Both CRL4 complex and COP9 signalosome have
been reported to regulate MDM2-mediated p53 stability43,44.
Further analysis showed that many DCAF1-associating proteins
are known to regulate MDM2 function45 (Supplementary
Table 2). In addition, we found that DCAF1 bound to MDM2
in activated T cells (Supplementary Fig. 4c), suggesting a
potential role for DCAF1 in MDM2-promoted p53
poly-ubiquititation and degradation. To test this, we deleted
DCAF1 in human osteosarcoma U2OS cells by using CRISPR-
Cas9-sgRNA-mediated genome editing via lentivirus-mediated
gene delivery46. DCAF1 deletion led to reduced expansion
of U2OS cells (Supplementary Fig. 5a), increased p53
protein expression (Supplementary Fig. 5b) and substantially
prolonged half-life of p53 (Supplementary Fig. 5c). Importantly,
MDM2-promoted p53 poly-ubiquitination in U2OS cells was
greatly reduced on DCAF1 deletion (Fig. 7i), suggesting that
DCAF1 was required for MDM2-promoted poly-ubiquitination
of p53 and p53 degradation. Aforementioned findings reveal a
critical role of DCAF1 in mediating p53 degradation, potentially
by regulating MDM2-promoted p53 poly-ubiquitination.
p53 is required for DCAF1-controlled cell cycle entry. p53
suppresses cell growth and cell cycle entry38,41,47. The findings
that DCAF1-deficient T cells failed to grow in size and to enter
cell cycle associating with a drastic stabilization of p53 prompted
us to study whether p53 is functionally important for
DCAF1-controlled T-cell function. To address this question, we
investigated whether and what DCAF1-dependent function(s)
could be restored by deleting p53 in DCAF1-deficient cells. The
Cd4Cre;Dcaf1fl/fl;p53 / mice were born with grossly normal
phenotype at young age. Similar to Cd4Cre;Dcaf1fl/fl mice,
Cd4Cre;Dcaf1fl/fl;p53 / mice showed largely normal T-cell
development in the thymus (Supplementary Fig. 6a,b)
but impaired mature T-cell maintenance in the periphery
(Supplementary Fig. 6b,c). On TCR stimulation, like naive
Cd4Cre;Dcaf1fl/fl T cells, naive Cd4Cre;Dcaf1fl/fl;p53 / T cells
failed to grow in size (Fig. 8a) and to divide (Fig. 8b) with
abrogated cell cycle entry (Fig. 8c). Of note, the upregulation
of c-Myc, another critical factor for cell growth and cell cycle,
was defective in the absence of DCAF1 regardless of p53
expression (Fig. 8d).
Nevertheless, the dispensable role of p53 in cell cycle entry of
naive T cells could be due to the failed cell growth, since cell
growth occurs slightly earlier than cell cycle entry in naive T cells
after TCR activation (Fig. 1a–d). To specifically examine how
DCAF1–p53 axis regulates cell cycle entry, we deleted DCAF1
after bypassing the growth phase in ERCre;Dcaf1fl/fl;p53 /
T cells. Timed DCAF1 deletion in TCR-activated ERCre;
Dcaf1fl/fl;p53 / T cells did not apparently affect cell growth
(Supplementary Fig. 6d). We found that the cell proliferation
defect of ERCre;Dcaf1fl/fl T cells was substantially restored when
p53 was deleted (Fig. 8e), suggesting that p53 is involved in
DCAF1-dependent cell cycle regulation. Encouraged by this
finding, we examined IL-2-promoted cell cycle entry of quiescent
effector ERCre;Dcaf1fl/fl;p53 / T cells. In the absence of p53,
DCAF1-deficient effector T cells entered cell cycle at a rate close
to wild-type T cells on IL-2 stimulation (Fig. 8f). We also noticed
that the c-Myc upregulation in DCAF1-deficient effector T cells
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during IL-2-stimulated cell cycle entry from quiescence was
restored on p53 deletion (Fig. 8g). Therefore, DCAF1 controls cell
cycle entry through p53. Collectively, aforementioned findings
suggest that DCAF1 and p53-dependent programme controls
cell cycle entry from quiescence and yet DCAF1-dependent,
p53-independent programme dictates cell growth.
Discussion
The majority of the cells in adult tissues including mature T cells
are maintained in a quiescent state with a low rate of cell size
growth (biomass increase due to enhanced biosynthesis) and
proliferation. Disturbances of the homeostasis, such as those
inflicted by injury, infection and inflammation, often trigger cells
to exit quiescence and to enter cell cycle, followed by
rapid proliferation to correct the disturbance and to restore
homeostasis. Cell size growth is imperative for the normal
function of proliferating cells to compensate for the halving of
cellular constituents for each division48. Thus, cell growth, cell
cycle entry and subsequent proliferation are fundamental
processes for a cell to respond to changing microenvironment
and to maintain homeostasis. In particular, proper coordination
of cell growth and cell cycle entry of T cells is essential for their
clonal expansion and function to mount effective immune
response. Nonetheless, little is known about how cell cycle
entry is controlled and even less about how cell size growth is
regulated49,50. One of the difficulties to study the biochemistry
and genetic requirements for cell growth versus cell cycle entry is
the lack of robust experimental systems to clearly distinguish
these processes because they often occur simultaneously and
appear inseparable. In this study, using activated naive and
effector T cells as model systems, we readily distinguished cell
growth and cell cycle entry phases based on the timing,
morphological, biochemical and molecular criteria. Taking
advantage of such a system, we identified DCAF1 a highly
upregulated factor in activated T cells and revealed a pivotal role
for DCAF1 in controlling T-cell function and T-cell-mediated
anti-viral and autoimmune responses.
Over-exuberant T-cell growth and proliferation are associated
with and required for the development of various diseases
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including inflammation, autoimmunity and leukaemia. Inhibiting
T-cell growth and cell cycle entry of aberrantly activated T cells
are effective ways to treat these disorders. This study revealed a
fundamental requirement of DCAF1 for activation-induced cell
growth and cell cycle entry and showed that interfering with
DCAF1 led to defective expansion of both T cells and tumour
cells. Therefore, DCAF1 is central to the critical steps towards
aberrant cell expansion and thus could be a useful therapeutic
target for treating inflammation and cancer. In addition, because
DCAF1 is a cellular protein targeted by Vpr of HIV9,
understanding the function of DCAF1 in immune cells will
shed light on how HIV evades and undermines immune function.
Recent studies showed that HIV evades innate defense system in
macrophages through DCAF1 (refs 10,11). We now found that
perturbation of DCAF1 led to decreased numbers of naive,
effector and memory T cells (major cell types targeted by HIV)
under steady state and the abrogation of T-cell response towards
virus infection. These findings suggest that one way that HIV
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4-hydroxy-tamoxifen. (f,g) CD4þ naive T cells of different genotypes were activated by anti-CD3 and anti-CD28 for 5 days to generate effector T cells in
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undermines T-cell function may be by interfering with DCAF1
function. It thus suggests that blocking Vpr–DCAF1 interaction
may help preserve T-cell population and function against HIV.
The down-modulation of p53 by TCR signalling is critical for
T-cell proliferation38. The molecular mechanisms underlying
TCR-induced p53 downregulation are, however, unclear. This
study revealed that DCAF1 was upregulated on TCR stimulation
and required for p53 degradation. It therefore suggests that
DCAF1 is an important factor relaying TCR signalling to
modulate p53 expression for a proper T-cell proliferation and
function. Because we found that DCAF1 was required to
destabilize p53, a factor regulates both cell metabolism47 and
cell cycle entry38,41, we posited that p53 was an important
downstream target of DCAF1 for both cell growth and cell cycle
entry. We, however, found that p53 deletion restored the cell
cycle entry of DCAF1-deficient cells but had no beneficial effect
on the cell growth of these cells. While the findings will not rule
out a role for p53 in DCAF1-controlled cell growth, it suggests
that p53-independent pathway(s) are more important. One of
these pathways could involve c-Myc. c-Myc is important for both
cell growth and proliferation2. During T-cell growth, c-Myc failed
to be upregulated in the absence of DCAF1 regardless of p53
expression. Therefore, c-Myc-controlled cell growth is regulated
by p53-independent programme(s) downstream of DCAF1.
Nonetheless, the c-Myc expression during cell cycle entry
appeared to be controlled by a DCAF1–p53-dependent
programme, because p53 deletion restored c-Myc expression to
a normal level in DCAF1-deficient effector T cells during
cytokine IL-2-stimulated cell cycle entry from quiescence. It
indicates that c-Myc expression is regulated by discrete genetic
programmes during cell growth and cell cycle entry: p53 is
dispensable for c-Myc expression during cell growth, but p53 is
important to suppress c-Myc expression during cell cycle entry
from quiescence. DCAF1–p53 signalling pathway identified in
this study sheds a new light on how TCR signalling and cell cycle
regulation co-opt to ensure a proper T-cell function during
immune responses.
DCAF1 functions through diverse mechanisms including
regulating protein poly-ubiquitination, mono-ubiquitination and
phosphorylation13,23–25. We found that DCAF1 was required to
destabilize p53 protein. One of the mechanisms underlying
DCAF-controlled p53 degradation could be related to MDM2,
because DCAF1 bound to MDM2 and to many proteins that are
known to regulate MDM2 function. Importantly, MDM2-
promoted poly-ubiquitination of p53 was impaired when
DCAF1 expression was defective. In addition, because we found
that DCAF1 belonged to a mega-complex-containing CRL4
complex and COP9 signalosome in T cells, it is plausible that
other components of this mega-complex also regulate p53 protein
stability. In fact, CUL4A (a CRL4 complex subunit), CSN2 and
CSN6 (COP9 signalosome subunits) have been shown to regulate
p53 degradation43,44,51. DCAF1 thus appears to control p53
stability through multiple mechanisms. A comprehensive
understanding of the precise mechanisms underlying DCAF1-
dependent control of p53 is therefore of interest warranting
further studies. We found that, besides regulating p53, DCAF1 is
critical for c-Myc expression independent of p53 during cell
growth. The underlying mechanism, however, remains elusive at
this moment. The finding that DCAF1 deletion consistently led to
reduced mRNA expression of c-Myc during cell growth implies
that DCAF1 may control c-Myc expression through factors
important for transcription and/or epigenetics, for example,
TET (Ten-eleven translocation methylcytosine dioxygenase)
proteins12,13. Therefore, in light of the current finding that
DCAF1 was critical for T-cell function by controlling cell growth
and cell cycle entry via distinct molecular programmes, it is of
interest to comprehensively investigate the exact mechanisms
underlying the essential and diverse functions of DCAF1 during
these fundamental biological processes.
Methods
Mice. Dcaf1fl/fl, p53 / , Rag1 / , SMARTA, Cd4Cre, ERCre and CD45.1 con-
genic wild-type mice were on C57BL/6 background. All mice were housed and bred
under specific pathogen-free conditions in the animal facility at the University of
North Carolina at Chapel Hill. Eight- to 16-week old, age- and sex-matched mice
were used for animal experiments. All mouse experiments were approved by
Institution Animal Care and Use Committee of the University of North Carolina.
Flow-cytometry and cell sorting. Lymphocytes were isolated from the thymus,
spleen and peripheral lymph nodes of age- and sex-matched mice of 8–16 weeks of
age. Fluorescence-conjugated antibodies for CD4 (Cat#100428, 1:400), CD8
(Cat#100722, 1:400), CD45.1 (Cat#110718, 1:400), CD45.2 (Cat#109814, 1:400),
CD25 (Cat#102008, 1:400), CD44 (Cat#103016, 1:400), CD62L (Cat#104412, 1:400)
and CD69 (Cat#104508, 1:400) were purchased from Biolegend. Annexin V (BD
Biosciences, 550474) and 7AAD (BD Biosciences, 559925) staining were used to
assess apoptosis. The staining was performed as per manufacturer’s protocols. For
cell sorting, CD4þ T cells were enriched by MACS (Miltenyi Biotec, 130-049-201)
and then stained with fluorescence-conjugated antibodies. Stained cells were either
analysed on the LSRII station (BD Biosciences) or sorted on the Moflow cell sorter
(Dako cytomation, Beckman coulter) by the flow facility of the University of North
Carolina at Chapel Hill. FACS data were analysed with FlowJo software (TreeStar).
T-cell activation and proliferation. T cells were activated with anti-CD3 (2c11)
and anti-CD28 (27.51) in Bruff’s medium supplemented with 10% (vol/vol) FBS
and 1% (vol/vol) penicillin/streptomycin. For carboxyfluorescein succinimidyl ester
(CFSE) dilution assay, T cells were labelled in 2 mM CFSE (Life Technologies,
C1157) and cultured in the presence of 2 ngml 1 IL-2 (BioLegend, 575406). For
BrdU incorporation assay, cultured T cells were pulsed with BrdU for 1 h prior to
harvest, stained with BrdU staining kit as per manufacture’s protocol (BD
Pharmingen, 559619) and analysed by flow-cytometry. For cells from ERCre;D-
caf1fl/fl mice, 1 mM of 4-hydroxy-tamoxifen (Sigma, H7904) was added to the
culture to induce the deletion of the floxed Dcaf1 alleles at the time of T-cell
activation. For p53 protein expression assay, 20 mM of MG132 (Santa Cruz,
sc-201270A) was added into cell culture 4 h prior to harvest. For p53 half-life assay,
1 mg of cycloheximide (CHX) (Sigma, C7698) was added into cell culture medium
at the indicated time point.
Knockout of DCAF1 by CRISPR/Cas9 system in human U2OS cells. Con-
struction of CRISPR-DCAF1 plasmids: DNA oligos targeting the protein-coding
region of human Dcaf1 (Dcaf1-1: 50-ATGTACCACTACTGTAGTCA-30 ; Dcaf1-2:
50-GACTACAGTAGTGGTACATG-30) were ligated into lentiviral vector Lenti-
sgRNA-Cas9–GFP, which was modified from LentiCRISPR52 by replacing
puromycin-resistance gene with green fluorescent protein (GFP) gene.
CRISPR-Dcaf1 and CRISPR-control lentivirus production and enrichment.
HEK293T cells were transfected with 15 mg of lentiCRISPR plasmids, 15 mg of
packaging plasmids (5mg of psPAX2, 10 mg of pMD2.G) using a calcium phosphate
transfection reagent. After 48 h, viruses were harvested, filtered through 0.45-mm
syringe filters and concentrated by ultracentrifugation at 26,000 r.p.m. in a Beck-
man SW28 ultracentrifuge rotor for 90min at 4 C and then resuspended with 1ml
MyCoy’s Medium.
Cell transduction and transfection. For transduction of U2OS cells with
CRISPR-Dcaf1 lentivirus, U2OS cells were seeded onto a 24-well plate at a con-
centration of 0.75 105 per well on day 0. Transduction was performed in fresh
media supplemented with 8 mgml 1 polybrene (Sigma-Aldrich, AL-118) on day 1.
Transduced U2OS cells were reseeded onto a 10-cm dish on day 3 and transfected
with pCDNA–Flag–MDM2 and pCMV–HA–Ubiquitin plasmids using FuGENE 6
transfection reagent on day 4. Cells were treated with 20 mM of proteasome inhi-
bitor MG132 (sc-201270A) for 4 h before harvest on day 6.
Bone marrow chimera. Bone marrow cells were isolated from age- and gender-
matched Cd4Cre;Dcaf1fl/fl mice (CD45.2þ ) and wild-type mice (CD45.1þ
CD45.2þ ). Bone marrow cells of different origins were mixed at the ratio of 1:1
and transferred retro-orbitally into sub-lethally irradiated (500 cGy) wild-type
(CD45.1þ ) or Rag1 / mice. T-cell population and function analysis were per-
formed at 8–10 weeks post cell transfer.
T-cell adoptive transfer and LCMV infection. CD4þ T cells were purified from
Cd4Cre;Dcaf1fl/þ ;SMARTA (CD45.2þ ) and Cd4Cre;Dcaf1fl/fl;SMARTA
(CD45.1þCD45.2þ ) mice by MACS. Cells of different origins were mixed at the
ratio of 1:1 and then transferred retro-orbitally into wild-type mice (CD45.1þ ).
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Twenty-four hour post transfer, recipient mice were injected i.p. with 2 105 p.f.u.
of LCMV (Armstrong strain). T-cell populations in the spleens were assessed by
flow-cytometry 5 days after the virus infection.
Eliciting EAE. Mice (12- to 16-week old) were immunized s.c. with 50 mg of
MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK, AnaSpec) and 500 mg of
Mycobacterium tuberculosis (Difco) emulsified in incomplete Freund’s adjuvant
(IFA) (Difco). In addition, the animals received 200 ng of pertussis toxin (List
Biological Laboratories) i.p. on days 0 and 2. The severity of EAE was monitored
and graded on a clinical score of 0 to 5: 0¼ no clinical signs; 1¼ limp tail;
2¼ paraparesis (weakness, incomplete paralysis of one or two hind limbs);
3¼ paraplegia (complete paralysis of two hind limbs); 4¼ paraplegia with forelimb
weakness or paralysis; 5¼moribund or death. The statistical significance was
analysed by nonparametric Mann–Whitney’s U-test.
Immunoblotting IP and MS. Protein extracts were resolved by AnyKD
SDS–PAGE gel (Bio-Rad, 4569034) and transferred to a polyvinylidene fluoride
membrane (Millipore) and analysed by immunoblotting with the following
antibodies: b-actin, Santa Cruz (I-19), WB (1:2,000); Rb, BD Pharmingen
(G3-245), WB (1:2,000); DCAF1, ProteinTech (11612-1-AP), WB (1:2,000), IP
(1:200); p53, Leica (IMX25), WB (1:2,000), IP (1:200); p21 Santa Cruz (F-5), WB
(1:500); c-Myc, Cell Signaling (D84C12), WB (1:2,000); p27, Cell Signaling
(SX53G8.5), WB (1:2,000); Cyclin D3, Cell Signaling (DCS22), WB (1:1,000);
Cyclin E, Cell Signaling (HE12), WB (1:1,000); MDM2 (2A10), gift from Dr
Yanping Zhang, WB (1:200), IP (1:50). Images of western blot have been cropped
for presentation. Full size images are presented in Supplementary Fig. 7.
To identify DCAF1-interacting proteins in T cells, CD4 T cells were purified by
MACS and activated by plate bound anti-CD3 and anti-CD28 for 24 h. The cells
were treated with MG132 for 4 h prior to harvest. Cells were lysed in NP40 lysis
buffer (1% Nonidet P-40, 50mM Tris (pH 7.5), 150mM NaCl, 10% glycerol)
containing protease inhibitor cocktail (Roche Molecular Biochemicals) and
MG132. The crude lysates were cleared by centrifugation at 14,000 r.p.m. at 4 C
for 15min. The supernatant was divided into two parts and incubated with agarose
beads (Santa Cruz, sc-2003) that conjugated with DCAF1 antibody or rabbit IgG in
cold room overnight. The immunocomplex was washed four times with NP40 lysis
buffer and then three times with PBS. Associated proteins were eluted by adding
2 Laemmli sample buffer (Bio-Rad, 1610737) and incubated at 95 C for 5min.
The eluted proteins were resolved in SDS–PAGE gel. Protein samples were excised
into 20 slices according to molecular weight and subjected to in-gel digestion with
trypsin (Promega, V5113). The gel extracts were dried in a SpeedVac lypholizer
and stored at  80 C until further analysis.
The products of immunoprecipitation were then subjected to MS. MS analyses
were performed using an LTQ Orbitrap Velos (Thermo Scientific, Bremen,
Germany) coupled with a nanoLC-Ultra system (Eksigent, Dublin, CA). Peptides
were resuspended in 30ml HPLC buffer A (0.1% formic acid in water) and 5 ml was
loaded onto an IntegraFrit column (New Objective, C18). The peptides were eluted
at a flow rate of 250 nlmin 1 with a linear gradient from 10 to 40% buffer B
(0.1% formic acid in acetonitrile) for 130min, followed by 5% buffer B for another
10min. The MS was programmed to acquire spectra in a data-dependent and
positive ion mode at a spray voltage of 2.1 kV using the XCalibur software (version
2.1, Thermo Scientific). Survey scans were performed in the Orbitrap analyser at a
resolution of 60,000 over a mass range between m/z 300–1,800. For each cycle, the
top 15 most intense ions were subjected to CID fragmentation in the LTQ Orbitrap
with normalized collision energy at 35% and activation Q 0.25; dynamic exclusion
was enabled. Selected ions were repeated once and then excluded from further
analysis for 60 s. Unassigned ions or those with a charge of 1þ were rejected.
Maximum ion accumulation times were 400ms for each full MS scan and
200ms for tandem MS (MS/MS) scans. One microscan was acquired for each
MS and MS/MS scan.
All the raw files obtained from the LTQ Orbitrap were processed through the
Andromeda and MaxQuant software suite (version 1.2.2.5) with the default
settings. The MS/MS spectra were searched against UniProt mouse database
(release date: 30 November 2010; 20,248 entries). A database that contains
contamination proteins was also used. Peptides that matched the contaminated
protein database were excluded. Trypsin was selected as enzyme and a maximum
of two missed cleavage peptides was allowed. Oxidation (M) was set to be a variable
modification. Peptide and MS/MS tolerance were set to be 7.5 p.p.m. and 0.5Da,
respectively. Up to two missed cleavage sites were allowed per peptide. Only
peptides with a minimum length of seven amino acids were considered for
identification. Peptide and protein identifications were filtered to a maximum 1%
and 5% false discovery rate, respectively. The MS proteomics data have been
deposited to the ProteomeXchange Consortium53 via the PRIDE partner
repository54 with the data set identifier PXD003180.
RNA preparation and real-time PCR. Total RNA was prepared from T cells using
TRIzol reagent (Invitrogen, 15596-026) as per manufacturer’s instructions, and was
reverse-transcribed into complementary DNA with Superscript III reverse tran-
scriptase kit (Bioline, BIO-65054). The Taqman probes of p21 (Mm04205640_g1),
c-Myc (Mm00487804), Bax (Mm00432051), Dcaf1 (Mm01226827_g1) and
Hprt (Mm01545399) were from Applied Biosystems and Quantitative PCR was
performed using SensiFastTM Probe Lo-ROX Kit (Bioline, BIO-84020) on
ABI9700 real-time PCR system.
Statistical analysis. Data analysis was processed and presented by Prism
(GraphPad, San Diego). Statistical significance was determined by Student’s t-test
unless stated otherwise. A P value of o0.05 was considered significant.
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